Recombinant human tissue-type plasminogen activator therapy in acute thromboembolic stroke
1987
✓ Systemic fibrinolytic therapy for acute stroke is no longer recommended because of resulting systemic fibrinolysis and the risk of intracerebral hemorrhage. Human tissue-type plasminogen activator (TPA) is a native enzyme that converts plasminogen to plasmin with subsequent clot lysis. The affinity for plasminogen is increased several-fold when the substrate is bound to fibrin. At appropriate dosage, “clot-specific” throm-bolysis may be achieved at the surface of the thrombus without creating systemic fibrinolysis. The authors designed a study to evaluate the effect of intravenous TPA administered 2 hours after acute thromboembolic stroke in rats. This time course was chosen to simulate an analogous clinical situation. Middle cerebral artery embolic stroke was caused by intracarotid injection of 0.025 cc of human blood clot in 16 rats. Regional cerebral blood flow, measured by the hydfogen clearance technique, and electroencephalographic (EEG) recordings were obtained every 30 minutes for 5 hours after ...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
30
References
91
Citations
NaN
KQI